Searching across hundreds of databases
Inhibition of monoacylglycerol lipase (MAGL), the primary enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain, produces profound anti-inflammatory and neuroprotective effects and improves synaptic and cognitive functions in animal models of Alzheimer's disease (AD). However, the molecular mechanisms underlying the beneficial effects produced by inhibition of 2-AG metabolism are still not clear. The cannabinoid receptor type 2 (CB2R) has been thought to be a therapeutic target for AD. Here, we provide evidence, however, that CB2R does not play a role in ameliorating AD neuropathology produced by inactivation of MAGL in 5XFAD APP transgenic mice, an animal model of AD. We observed that expression of APP and β-secretase as well as production of total Aβ and Aβ42 were significantly reduced in APP transgenic mice lacking CB2R (TG-CB2-KO) treated with JZL184, a selective and potent inhibitor for MAGL. Inactivation of MAGL also alleviated neuroinflammation and neurodegeneration in TG-CB2-KO mice. Importantly, TG-CB2-KO mice treated with JZL184 still exhibited improvements in spatial learning and memory. In addition, MAGL inhibition prevented deterioration in expression of important synaptic proteins in TG-CB2-KO mice. Our results suggest that CB2R is not required in ameliorating neuropathology and preventing cognitive decline by inhibition of 2-AG metabolism in AD model animals.
Pubmed ID: 28733897 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets beta-Amyloid 17-24
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis monoclonal targets β-Actin
View all literature mentionsThis polyclonal secondary targets IgG
View all literature mentionsThis polyclonal targets Rat NMDAR2B
View all literature mentionsThis polyclonal targets NMDAR2A
View all literature mentionsThis monoclonal targets NMDAR1
View all literature mentionsThis monoclonal targets Glutamate Receptor 2 (GluR2), aa175-430
View all literature mentionsThis polyclonal targets Glutamate receptor 1
View all literature mentionsThis polyclonal targets BACE1 B690 C-Terminal Rabbit
View all literature mentionsThis polyclonal targets beta Amyloid (1-42)
View all literature mentionsThis monoclonal targets beta-Amyloid 17-24
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
